heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
=== Circulatory and gas exchange system === The body cavity contains the circulatory or haemal system. The vessels form three rings: one around the mouth (the hyponeural haemal ring), another around the digestive system (the gastric ring), and the third near the aboral surface (the genital ring). The heart beats about six times a minute and is at the apex of a vertical channel (the axial vessel) that connects the three rings. Blood does not contain a pigment such as heme, but is probably used to transport nutrients around the body. Gas exchange mainly takes place through gills known as papulae, which are thin-walled bulges along the aboral surface of the arms. Oxygen is transferred from these to the coelomic fluid, which moves gas around the body.
== Modern colloquial usage == The term "culottes" in more recent French describes women's underpants, an article of clothing that has little or no relation to the historical culottes, but now also refers to apparent skirts that are actually split with two legs. The term sans-culottes has been used colloquially to mean not wearing underpants.
=== Research === A capsaicin transdermal patch (Qutenza) for the management of pain due to post-herpetic neuralgia was approved in 2009, as a therapeutic by both the U.S. Food and Drug Administration (FDA) and the European Union. One 2017 review of clinical studies found, with limited quality, that high-dose topical capsaicin (8%) compared with control (0.4% capsaicin) provided moderate to substantial pain relief from post-herpetic neuralgia, HIV-neuropathy, and diabetic neuropathy. Although capsaicin creams have been used to treat psoriasis for reduction of itching, a review of six clinical trials involving topical capsaicin for treatment of pruritus concluded there was insufficient evidence of effect. Low-quality evidence indicates that oral capsaicin may decrease LDL cholesterol levels moderately.
Cholesterol ratio: This ratio compares the levels of LDL to HDL. Trans fat behaves like saturated fat by raising the level of LDL, but, unlike saturated fat, it has the additional effect of decreasing levels of HDL. The net increase in LDL/HDL ratio with trans fat is approximately double that due to saturated fat. (Higher ratios are worse.) One randomized crossover study published in 2003 comparing the effect of eating a meal on blood lipids of (relatively) cis and trans fat rich meals showed that cholesteryl ester transfer (CET) was 28% higher after the trans meal than after the cis meal and that lipoprotein concentrations were enriched in apolipoprotein(a) after the trans meals. C-reactive protein (CRP): A study of over 700 nurses showed that those in the highest quartile of trans fat consumption had blood levels of CRP that were 73% higher than those in the lowest quartile.
=== 17 October === The SAF and the RSF traded blame for a drone attack on a community meeting in Al-Mazroub, North Kordofan that killed 17 people, including Nazir Suleiman Jaber Juma’a Sahl, the leader of the Majaneen tribe. The JDF claimed to have retaken Abu Gamra. The SAF and allied forces claimed to have repelled an RSF attack on El Fasher, destroying 10 RSF vehicles and capturing two others.
Sources: en.wikipedia.org
Electrotaxis, also known as galvanotaxis (named after Galvani), is the directed motion of biological cells or organisms guided by an electric field or current. The directed motion of electrotaxis can take many forms, such as; growth, development, active swimming, and passive migration. A wide variety of biological cells can naturally sense and follow DC electric fields. Such electric fields arise naturally in biological tissues during development and healing. These and other observations have led to research into how applied electric fields can impact wound healing An increase in wound healing rate is regularly observed and this is thought to be due to the cell migration and other signaling pathways that are activated by the electric field. Additional research has been conducted into how applied electric fields impact cancer metastasis, morphogenesis, neuron guidance, motility of pathogenic bacteria, biofilm formation, and many other biological phenomena.
== History == Elagolix was first described in the literature in 2005. It was originally developed by the pharmaceutical company Neurocrine Biosciences, and was later developed together by Neurocrine Biosciences and AbbVie (previously Abbott Laboratories). In June 2010, Neurocrine Biosciences and Abbott announced a global agreement to develop and commercialize elagolix for the treatment of endometriosis. The medication completed phase III clinical trials for endometriosis in November 2016. Two phase III clinical trials, the Elaris Endometriosis I and II (EM-I and EM-II) studies, were conducted. The studies included almost 1,700 women, about 950 of whom were treated with elagolix. In September 2017, AbbVie filed a New Drug Application (NDA) for elagolix for the treatment of pain associated with endometriosis in the United States. The medication was approved by the FDA for the treatment of endometriosis-associated pain in the United States on 23 July 2018. It was the first new medication to be approved by the FDA for the treatment of endometriosis in more than a decade. Elagolix was the first member of a new class of GnRH modulators described as "second-generation" due to their non-peptide and small-molecule nature and oral activity to be marketed. A second member of this group, relugolix (brand name Relumina), was introduced in Japan in January 2019. In addition to endometriosis, elagolix is under development for the treatment of uterine fibroids and menorrhagia. It is in phase III clinical trials for these indications.
Collagen alpha-1(XV) chain is a protein that in humans is encoded by the COL15A1 gene. This gene encodes the alpha chain of type XV collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Type XV collagen has a wide tissue distribution but the strongest expression is localized to basement membrane zones so it may function to adhere basement membranes to underlying connective tissue stroma. Mouse studies have shown that collagen XV deficiency is associated with muscle and microvessel deterioration. Type XV collagen is known to be a tumor suppressor that can be used to understand tumor cells environment. Type XV collagen provides the membrane with support and cell anchorage but does not typically have a tight structural network. Changes of collagen XV can be known to lead to cancer-like behavior in tissues. The loss of collagen XV would no longer provide structural support for the membrane, which can cause tumor cells to invade the basement membrane; prompting possible metastasis. The over expression of collagen XV is known to be found in cervical cancer. For possible future medical purposes the lack of collagen XV present in tissues can be a means for indication of an invasive tumor.
The mycobiont (fungal partner) of the lichen Lecidea tessellata has been shown to produce confluentic acid when cultured without its algal photobiont partner. Confluentic acid has also been reported from mycobiont cultures of Parmelina carporrhizans. Confluentic acid is produced by almost all species of the genus Immersaria, which is usually accompanied by 2'-O-methylmicrophyllinic acid. The absence of confluentic acid distinguishes Inoderma nipponicum, from others in genus Inoderma, which typically contain this chemical. The only character reliably distinguishing Porpidia contraponenda and the morphologically similar Porpidia cinereoatra is their secondary chemistry: the former contains 2'-O-methylmicrophyllinate and the latter has confluentic acid. A chemosyndrome is a set of biosynthetically related compounds produced by a lichen. The confluentic acid chemosyndrome was identified in several lichens in the family Lecideaceae; it contains confluentic acid as the major metabolite, and minor amounts of 2'-O-methylperlatolic acid, olivetonide monomethyl ether, and 2'-O-methylmicrophyllinic acid. Not just limited to lichen-forming fungi, confluentic acid has also been reported from the Brazilian plant Himatanthus sucuuba, highlighting the compound's broader biological distribution.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.